Your browser doesn't support javascript.
loading
Predictors of clinically significant quality of life impairment in Parkinson's disease.
Santos García, Diego; de Deus Fonticoba, Teresa; Cores, Carlos; Muñoz, Guillermo; Paz González, Jose M; Martínez Miró, Cristina; Suárez, Ester; Jesús, Silvia; Aguilar, Miquel; Pastor, Pau; Planellas, Lluis; Cosgaya, Marina; García Caldentey, Juan; Caballol, Nuria; Legarda, Inés; Hernández Vara, Jorge; Cabo, Iria; López Manzanares, Luis; González Aramburu, Isabel; Ávila Rivera, María A; Catalán, Maria J; Nogueira, Víctor; Puente, Víctor; Ruíz de Arcos, María; Borrué, Carmen; Solano Vila, Berta; Álvarez Sauco, María; Vela, Lydia; Escalante, Sonia; Cubo, Esther; Carrillo Padilla, Francisco; Martínez Castrillo, Juan C; Sánchez Alonso, Pilar; Alonso Losada, Maria G; López Ariztegui, Nuria; Gastón, Itziar; Clavero, Pedro; Kulisevsky, Jaime; Blázquez Estrada, Marta; Seijo, Manuel; Rúiz Martínez, Javier; Valero, Caridad; Kurtis, Mónica; de Fábregues, Oriol; González Ardura, Jessica; Ordás, Carlos; López Díaz, Luis M; McAfee, Darrian; Martinez-Martin, Pablo; Mir, Pablo.
Affiliation
  • Santos García D; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. diegosangar@yahoo.es.
  • de Deus Fonticoba T; CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.
  • Cores C; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Muñoz G; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Paz González JM; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Martínez Miró C; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Suárez E; CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.
  • Jesús S; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Aguilar M; CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), Álava, Spain.
  • Pastor P; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.
  • Planellas L; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.
  • Cosgaya M; Neurología, Clínica del Pilar, Barcelona, Spain.
  • García Caldentey J; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Caballol N; Centro Neurológico Oms 42, Palma de Mallorca, Spain.
  • Legarda I; Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain.
  • Hernández Vara J; Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Cabo I; Hospital Universitario Vall d´Hebron, Barcelona, Spain.
  • López Manzanares L; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • González Aramburu I; Hospital Universitario La Princesa, Madrid, Spain.
  • Ávila Rivera MA; CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), Álava, Spain.
  • Catalán MJ; Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Nogueira V; Consorci Sanitari Integral, Hospital General de L´Hospitalet, L´Hospitalet de Llobregat, Barcelona, Spain.
  • Puente V; Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Ruíz de Arcos M; Hospital Da Costa, Burela, Lugo, Spain.
  • Borrué C; Hospital del Mar, Barcelona, Spain.
  • Solano Vila B; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Álvarez Sauco M; Hospital Infanta Sofía, Madrid, Spain.
  • Vela L; Institut d'Assistència Sanitària (IAS) - Institut Català de la Salut, Girona, Spain.
  • Escalante S; Hospital General Universitario de Elche, Elche, Spain.
  • Cubo E; Fundación Hospital de Alcorcón, Madrid, Spain.
  • Carrillo Padilla F; Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Tarragona, Spain.
  • Martínez Castrillo JC; Complejo Asistencial Universitario de Burgos, Burgos, Spain.
  • Sánchez Alonso P; Hospital Universitario de Canarias, San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain.
  • Alonso Losada MG; Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  • López Ariztegui N; Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Gastón I; Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.
  • Clavero P; Complejo Hospitalario de Toledo, Toledo, Spain.
  • Kulisevsky J; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Blázquez Estrada M; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Seijo M; CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), Álava, Spain.
  • Rúiz Martínez J; Hospital de Sant Pau, Barcelona, Spain.
  • Valero C; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Kurtis M; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • de Fábregues O; Hospital Universitario Donostia, San Sebastián, Spain.
  • González Ardura J; Hospital Arnau de Vilanova, Valencia, Spain.
  • Ordás C; Hospital Ruber Internacional, Madrid, Spain.
  • López Díaz LM; Hospital Universitario Vall d´Hebron, Barcelona, Spain.
  • McAfee D; Hospital Universitario de Cabueñes, Gijón, Spain.
  • Martinez-Martin P; Hospital Rey Juan Carlos, Madrid, Spain, Madrid, Spain.
  • Mir P; Complejo Hospitalario Universitario de Orense (CHUO), Orense, Spain.
NPJ Parkinsons Dis ; 7(1): 118, 2021 Dec 16.
Article in En | MEDLINE | ID: mdl-34916528
ABSTRACT
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: NPJ Parkinsons Dis Year: 2021 Document type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: NPJ Parkinsons Dis Year: 2021 Document type: Article Affiliation country: Spain